ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics ...

LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage ...

ADAR1 Capital Management, 13.3% shareholder of Keros Therapeutics (NASDAQ:KROS), issued an open letter to the company related ...

AUSTIN - ADAR1 Capital Management, LLC, the major shareholder of Keros Therapeutics (NASDAQ:KROS), has urged the biotechnology firm to disclose the results of its strategic review before its upcoming ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Keros' cash and cash equivalents as of March 31, 2025 was $720.5 million compared to $559.9 million as of December 31, 2024. Based on current operating assumptions, Keros expects that its cash and ...

May 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...

AUSTIN - ADAR1 Capital Management, LLC, the major shareholder of Keros Therapeutics (NASDAQ:KROS), has urged the biotechnology firm to disclose the results of its strategic review before its ...

Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Keros ...

"KER-065 appears promising and may have the potential to benefit a broad spectrum of patients with DMD, from young ambulatory boys to older, non-ambulatory individuals.” - Liesbeth De Waele, MD, ...